Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics

Pediatric Pulmonology

Volumn 50, Issue , 2015, Pages S66-S73

  Goralski, Jennifer L ^a   Davis, Stephanie D ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

anti inflammatory; antibiotics; Cystic fibrosis; mucolytics; pipeline

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; AMELUBANT; AMIKACIN; AZITHROMYCIN; AZTREONAM; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CIPROFLOXACIN; COLISTIMETHATE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; ELUBRIXIN; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; FOSFOMYCIN; GLUTATHIONE; IBUPROFEN; LEUKOCYTE ELASTASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOFLOXACIN; MANNITOL; PLACEBO; SODIUM CHLORIDE; THIOL DERIVATIVE; TOBRAMYCIN; VANCOMYCIN; AMINOPHENOL DERIVATIVE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRY POWDER; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MUCOCILIARY CLEARANCE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; GENE DELETION; GENETICS; HOMOZYGOTE; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

AMINOPHENOLS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG THERAPY; GENE DELETION; HOMOZYGOTE; HUMANS; QUALITY OF LIFE; QUINOLONES; TREATMENT OUTCOME;

EID: 84941075466     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23253     Document Type: Review

References (76)

1. Mogayzel PJ, Jr., Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B, et al., Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187: 680-689.
2. McCoy K, Hamilton S, Johnson C,. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110: 889-895.
3. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study G. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
4. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
5. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ, Scientific Advisory G,. Investigators, Coordinators of Epidemiologic Study of Cystic F. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011; 46: 545-553.
6. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L,. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012; 47: 44-52.
7. Mainz JG, Schien C, Schiller I, Schadlich K, Koitschev A, Koitschev C, Riethmuller J, Graepler-Mainka U, Wiedemann B, Beck JF,. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros 2014; 13: 461-470.
8. Dentice R, Elkins M,. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2013; 6: CD007923.
9. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT,. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 1503-1509.
10. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT,. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-903.
11. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC,. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250.
12. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT, National Hypertonic Saline in Cystic Fibrosis Study G. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240.
13. Donaldson SH, Samulski D, LaFave C, Wu J, Zeman K, Salazar C, Bennett WD, Davis SD,. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatr Pulmonol 2013; 48: 210.
14. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F,. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010; 65: 379-383.
15. Dellon EP, Donaldson SH, Johnson R, Davis SD,. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 1100-1106.
16. Subbarao P, Balkovec S, Solomon M, Ratjen F,. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42: 471-476.
17. Rosenfeld M, Davis S, Brumback L, Daniel S, Rowbotham R, Johnson R, McNamara S, Jensen R, Barlow C, Ratjen F,. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol 2011; 46: 666-671.
18. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD, Group IS,. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012; 307: 2269-2277.
19. Subbarao P, Stanojevic S, Brown M, Jensen R, Rosenfeld M, Davis S, Brumback L, Gustafsson P, Ratjen F,. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013; 188: 456-460.
20. Daviskas E, Anderson SD, Eberl S, Young IH,. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008; 31: 765-772.
21. Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, et al., Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013; 12: 367-376.
22. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertson CF, Bye PT, Lesouef PN, Shadbolt B, et al., Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133: 1388-1396.
23. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, et al., Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185: 645-652.
24. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, Charlton B, Investigators CFS,. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-1080.
25. Althaus M,. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol 2013; 6: 3-12.
26. Coote KJ, Paisley D, Czarnecki S, Tweed M, Watson H, Young A, Sugar R, Vyas M, Smith NJ, Baettig U, et al., NVP-QB E170: an inhaled ENaC blocker with a reduced potential to induce hyperkalaemia. Br J Pharmacol 2015; 172: 2814-2826.
27. O'Riordan TG, Donn KH, Hodsman P, Ansede JH, Newcomb T, Lewis SA, Flitter WD, White VS, Johnson MR, Montgomery AB, et al., Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv 2014; 27: 200-208.
28. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al., Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
29. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP,. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014; 11: 342-350.
30. Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G,. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros 2012; 11: 419-426.
31. Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, Blanco-Aparicio M, Santoro D, Varoli G, Zibellini M, et al., Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatr Pulmonol 2014; 49: 1076-1089.
32. Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F,. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 2014; 13: 172-178.
33. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al., Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165: 847-856.
34. Ratjen F, Munck A, Kho P, Angyalosi G, Group ES,. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286-291.
35. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Morgan WJ,. Clinical use of tobramycin inhalation solution (TOBI(R)) shows sustained improvement in FEV1 in cystic fibrosis. Pediatr Pulmonol 2014; 49: 529-536.
36. Parkins MD, Elborn JS,. Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011; 5: 609-622.
37. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G,. Tobramycin inhalation powder for P. Aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46: 230-238.
38. Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, Murphy DM, Plant BJ,. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692-698.
39. Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M,. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care 2014; 59: 388-398.
40. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE,. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10: 54-61.
41. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB,. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928.
42. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ,. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-1134.
43. Tiddens HA, De Boeck K, Clancy JP, Fayon M, H GMA, Bresnik M, Derchak A, Lewis SA, Oermann CM, investigators As. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study. J Cyst Fibros 2015; 14: 111-119.
44. Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB,. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. Aeruginosa. J Cyst Fibros 2011; 10: 234-242.
45. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, et al., Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013; 12: 130-140.
46. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB,. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011; 66: 2398-2404.
47. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K,. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013; 12: 29-34.
48. Schuster A, Haliburn C, Doring G, Goldman MH, Freedom Study,. Efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68: 344-350.
49. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zavataro L, Campana S,. Italian Group for PaEiCF. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012; 67: 853-859.
50. Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, et al., A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT -1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 2015; 14: 507-514.
51. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ,. Mpex 204 Study G. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183: 1510-1516.
52. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM,. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev Respir Med 2015; 9: 13-22.
53. Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, Zalewski CK, Folio LR, Siegelman JR, Shallom S, et al., Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014; 11: 30-35.
54. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al., Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013; 68: 818-825.
55. McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM,. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS ONE 2013; 8: e69763.
56. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE, Phase FTISG,. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171-178.
57. Hayes D, Jr., Murphy BS, Mullett TW, Feola DJ,. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology 2010; 15: 184-186.
58. Maiz L, Canton R, Mir N, Baquero F, Escobar H,. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998; 26: 287-289.
59. Jennings MT, Boyle MP, Weaver D, Callahan KA, Dasenbrook EC,. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis - The PMEP trial: study protocol for a randomized controlled trial. Trials 2014; 15: 223.
60. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III, et al., Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
61. Marjanovic N, Bosnar M, Michielin F, Wille DR, Anic-Milic T, Culic O, Popovic-Grle S, Bogdan M, Parnham MJ, Erakovic Haber V,. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 2011; 63: 389-397.
62. Gillis RJ, Iglewski BH,. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol 2004; 42: 5842-5845.
63. Schogler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, et al., Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45: 428-439.
64. Siekmeier R, Hofmann T, Scheuch G,. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv Exp Med Biol 2015; 839: 13-24.
65. Konstan MW, Byard PJ, Hoppel CL, Davis PB,. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
66. Konstan MW, Schluchter MD, Xue W, Davis PB,. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089.
67. Lands LC, Milner R, Cantin AM, Manson D, Corey M,. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151: 249-254.
68. Lindstrom DR, Conley SF, Splaingard ML, Gershan WM,. Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. J Otolaryngol 2007; 36: 309-314.
69. Carlile GW, Robert R, Goepp J, Matthes E, Liao J, Kus B, Macknight SD, Rotin D, Hanrahan JW, Thomas DY,. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros 2015; 14: 16-25.
70. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, Investigators AC,. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
71. Jiang D, Persinger R, Wu Q, Gross A, Chu HW,. Alpha1-Antitrypsin promotes SPLUNC1-mediated lung defense against Pseudomonas aeruginosa infection in mice. Respir Res 2013; 14: 122.
72. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG,. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
73. Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A,. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD007168.
74. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, et al., Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013; 188: 83-89.
75. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL, Investigators CF,. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013; 12: 241-248.
76. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A, Investigators et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014; 13: 148-155.